WASHINGTON, Sept. 4,
2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR)
(the "Company") confirmed its previously issued guidance for the
third quarter and full year 2024 ahead of a previously scheduled
analyst event.
The Company provides forecasted sales only on a non-GAAP core
revenue basis because of the difficulty in estimating the other
components of GAAP revenue, such as currency translation,
acquisitions and divested product lines. For both the third
quarter and full year 2024, the Company continues to expect that
non-GAAP core revenue will be down low-single digits
year-over-year.
As previously announced, Danaher will hold an analyst meeting in
Washington, D.C. on September 5, 2024 beginning at approximately
10:00 a.m. ET. The event will be
hosted by Julie Sawyer Montgomery,
Executive Vice President, Diagnostics. A link to the webcast and
accompanying slide presentation will be available on the
"Investors" section of Danaher's website, www.danaher.com, under
the subheading "Events & Presentations." A replay of the video
webcast will be available following the presentation.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics
innovator, committed to accelerating the power of science and
technology to improve human health. Our businesses partner closely
with customers to solve many of the most important health
challenges impacting patients around the world. Danaher's advanced
science and technology - and proven ability to innovate - help
enable faster, more accurate diagnoses and help reduce the time and
cost needed to sustainably discover, develop and deliver
life-changing therapies. Focused on scientific excellence,
innovation and continuous improvement, our approximately 63,000
associates worldwide help ensure that Danaher is improving quality
of life for billions of people today, while setting the foundation
for a healthier, more sustainable tomorrow. Explore more
at www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical,
including the statements regarding the Company's anticipated
financial results for the third quarter and full year 2024 and any
other statements regarding events or developments that we believe
or anticipate will or may occur in the future are "forward-looking"
statements within the meaning of the federal securities laws. There
are a number of important factors that could cause actual results,
developments and business decisions to differ materially from those
suggested or indicated by such forward-looking statements and you
should not place undue reliance on any such forward-looking
statements. These factors include, among other things:
unanticipated, further declines in demand for our COVID-19 related
products, the impact of global health crises, the impact of our
debt obligations on our operations and liquidity, deterioration of
or instability in the global economy, the markets we serve and the
financial markets, uncertainties with respect to the development,
deployment, and use of artificial intelligence in our business and
products, uncertainties relating to national laws or policies,
including laws or policies to protect or promote domestic interests
and/or address foreign competition, contractions or growth rates
and cyclicality of markets we serve, competition, our ability to
develop and successfully market new products and technologies and
expand into new markets, the potential for improper conduct by our
employees, agents or business partners, our compliance with
applicable laws and regulations (including rules relating to
off-label marketing and other regulations relating to medical
devices and the health care industry), the results of our clinical
trials and perceptions thereof, our ability to effectively address
cost reductions and other changes in the health care industry, our
ability to successfully identify and consummate appropriate
acquisitions and strategic investments, our ability to integrate
the businesses we acquire and achieve the anticipated growth,
synergies and other benefits of such acquisitions, contingent
liabilities and other risks relating to acquisitions, investments,
strategic relationships and divestitures (including tax-related and
other contingent liabilities relating to past and future IPOs,
split-offs or spin-offs), security breaches or other disruptions of
our information technology systems or violations of data privacy
laws, the impact of our restructuring activities on our ability to
grow, risks relating to potential impairment of goodwill and other
intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws
applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of
the United States government with
respect to our production capacity in times of national emergency
or with respect to intellectual property/production capacity
developed using government funding, risks relating to product,
service or software defects, product liability and recalls, risks
relating to our manufacturing operations and fluctuations in the
cost and availability of the supplies we use (including
commodities) and labor we need for our operations, our
relationships with and the performance of our channel partners,
uncertainties relating to collaboration arrangements with
third-parties, the impact of deregulation on demand for our
products and services, the impact of climate change, legal or
regulatory measures to address climate change and our ability to
address stakeholder expectations relating to climate change, labor
matters and our ability to recruit, retain and motivate talented
employees representing diverse backgrounds, experiences and skill
sets, non-U.S. economic, political, legal, compliance, social and
business factors (including the impact of military conflicts),
disruptions relating to man-made and natural disasters, inflation
and the impact of our By-law exclusive forum provisions. Additional
information regarding the factors that may cause actual results to
differ materially from these forward-looking statements is
available in our SEC filings, including our 2023 Annual Report on
Form 10-K and Quarterly Report on Form 10-Q for the second quarter
of 2024. These forward-looking statements speak only as of the date
of this release and except to the extent required by applicable
law, the Company does not assume any obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events and developments or otherwise.
View original
content:https://www.prnewswire.com/news-releases/danaher-confirms-third-quarter-and-full-year-2024-guidance-302238099.html
SOURCE Danaher Corporation